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Conclusion: The analysis proposed can be used to perform 
automatic detection of MLC errors ≥0.5mm based on 
individual Linac performance characteristics. Automatic 
detection of MLC errors has potential in reducing costs and 
downtime in external beam radiotherapy. 
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Purpose or Objective: To assess the feasibility of using 
radiochromic film to aid the calorimetric determination of 
the dose-area product (DAP) in small fields by determining 
the uncertainty in film DAP measurements. 
 
Material and Methods: Dose measurements in small fields 
can be problematic. DAP methods with a detector much 
larger than the radiation field provide an alternative to 
conventional central-axis (CAX) dose measurements. DAP is 
the integrated dose over the area of the detector (Equ. 1) 
with units of Gy.cm2. In order to convert the measured DAP 
to the CAX dose the equivalent area of the beam is required. 
This is the area of an equivalent field with no penumbra (i.e. 
a step function profile). 
 
(1) 
Out of field doses can contribute considerably to the total 
dose when the detector is integrating over an area much 
larger than the field size. Film exposures with centimetre-
sized fields were performed on the Imaging and Medical 
Beamline (IMBL) at the Australian Synchrotron using HD-V2 
radiochromic film. Films were scanned using an Epson V700 
flatbed scanner. The equivalent beam area was calculated by 
two methods: by normalising the 2D optical density data to 
unity and either (a) integrating over the area of the detector, 
or (b) integrating horizontal and vertical profiles and 
calculating an area by the product of width and height. 
Uncertainties have been assessed for scan repeatability, 
scanner corrections, scanning conditions of calibration films, 
selection of normalisation value and the dynamic range of 
the film. 
 
Results: The most important contribution to the uncertainty 
in DAP measurements is the calculation of the beam area. In 
the IMBL beam dose rates are typically 50 – 3000 Gy/s 
depending on distance from the source. High dose film such 
as HD-V2 is necessary to measure the large doses, however 
the dynamic range of the film is not suited to low dose 
measurements. 
Preliminary measurements suggest an uncertainty of 1% to 
1.5% in the background dose (relative to CAX dose) can be 
expected. For a 10x10 mm2 field measured with a detector 
40 mm in diameter, a 1% uncertainty in background dose will 
result in a 12% uncertainty in DAP measurement. This is likely 
to be the limiting factor for DAP film measurements.  
Scan repeatability, scanner light intensity variation in the 
horizontal plane, scanner resolution and air gap between film 
and scanner window all introduce small uncertainties. These 
can be reduced by using systematic scanning techniques and 
averaging over multiple scans. 
 
Conclusion: Determination of the out of field dose was found 
to the dominant uncertainty in film DAP measurements. 
Further work is required to determine if a two-film approach 
can improve the uncertainty. The desired accuracy of <5% 
will require additional steps to reduce the uncertainty in the 
out of field dose. 
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Purpose or Objective: Pre-treatment evaluation of RapidArc 
plans with three different methods: Portal Dosimetry, Delta4 
and Epiqa and comparative study. 
 
Material and Methods: RapidArc plans are calculated by 
Eclipse V.10 AAA algorithm and treatments are delivered by 
Varian Clinac iX and 2100 accelerators. The pretreatment 
verification methods are Portal Dosimetry by Varian, 3D 
detector Delta4 by ScandiDos and the software Epiqa by 
EPIdos.  
 
Results: The comparative study is carried out on 100 
patients. The acceptance criteria used for gamma analysis 
are: local, dose difference from 3% to 4% and distance-to-
agreement from 3mm to 4mm. 
For Head & Neck treatments, the average value of Gamma 
Agreement Index (GAI) given by Portal Dosimetry is 98,17% 
with standard deviation of 1,41%, Delta4 gives 97,77% with 
standard deviation of 1,52% and Epiqa 97,54% with standard 
deviation of 1,60%. 
For Pelvis treatments, the average value of Gamma 
Agreement Index (GAI) given by Portal Dosimetry is 98,09% 
with standard deviation of 1,54%, Delta4 gives 98,19% with 
standard deviation of 1,30% and Epiqa 97,83% with standard 
deviation of 1,84%. 
For Encephalon treatments, the average value of Gamma 
Agreement Index (GAI) given by Portal Dosimetry is 98,31% 
with standard deviation of 1,49%, Delta4 gives 98,04% with 
standard deviation of 1,56% and Epiqa 99,01% with standard 
deviation of 1,38%. 
For Thorax & Abdomen treatments, the average value of 
Gamma Agreement Index (GAI) given by Portal Dosimetry is 
97,57% with standard deviation of 1,77%, Delta4 gives 97,92% 
with standard deviation of 1,41% and Epiqa 97,96% with 
standard deviation of 1,58%. 
Then, intentional errors were introduced in 3 plans in order 
to evaluate the capacity of each method to detect these 
errors. It was errors in terms of Monitor Units (MU) and 
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collimator angle. The results are based on the value of GAI: 
when the value is lower than 95%, the error is detected. 
Introduced errors are smaller and smaller in order to 
characterize error detection limits of each method. 
For Portal Dosimetry, it is possible to detect errors of 
collimator angle up to 4° and errors of Monitor Units up to 
3%. For Delta4, it is possible to detect errors of collimator 
angle up to 2° and errors of Monitor Units up to 2 %. For 
Epiqa, it is possible to detect errors of collimator angle up to 
2° and errors of Monitor Units up to 3%. 
 
Conclusion: In spite of their differences, the three pre-
treatment verification methods are able to detect different 
sort of errors in dose distributions. The comparative study 
gives us concordant results. Therefore, these data suggest 
the possibility of using only one routinely and complete the 
analysis with one of the other in case of problems. 
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Purpose or Objective: In this study, we compared patient 
therapy planning evaluation system, applying MLC log file, 
with quality assurance system using the fluence map 
obtained from measurement, in order to assess usefulness of 
patient dose analysis system. 
 
Material and Methods: To map out IMRT treatment planning, 
we used 4 targets and organ contours (multiple targets, 
virtual prostate, virtual head & neck, C type), along with 
IMRT phantom as presented in AAPM TG-119 Report. The 
treatment planning was implemented via Eclipse treatment 
planning system using 7 radiation field at an interval of 50º 
from 0o for both multiple targets and virtual prostate on one 
hand and using 9 radiation fields at an interval of 40º from 0o 
for both virtual head & neck and C type on the other hand. 
For dose limitation conditions for PTV and critical structure, 
we adopted the objectives specified in TG 119 Report. In 
relation to dose evaluation, point dose was evaluated by 
using CC13 chamber. The gamma index was analyzed for 
allowable limit of 3%/3mm by using MobiusFx system, a dose 
analysis software using MLC log file, in tandem with 2D array 
detector and Compass software that evaluates dose based on 
fluence map. 
 
Results: Dose distribution was calculated using treatment 
planning and Mobius system for 4 targets and then compared 
through three-dimensional gamma index based on the setting 
criteria for allowable limit of 3%/3mm. The results showed 
the pass rate of 99.5% in multiple targets, 100.0% in prostate, 
99.5% in head & neck, and 99.8% in C type. Based on results 
of analysis of gamma index for dose distribution, which was 
performed on the basis of dose distribution calculated by 
MobiusFX system and MLC log file actually investigated, the 
pass rate was found to be 100.0% in multiple targets, 100.0% 
in prostate, 99.7% in head & neck, and 99.5% in C type. 
Meanwhile, gamma index was analyzed based on dose 
distribution under treatment planning for 4 targets and dose 
distribution measured through Compass system, and the 
results indicated that the pass rate was 99.9% in multiple 
targets, 99.6% in prostate, 99.2% in head & neck, and 98.8% 
in C type. In addition, the results of point dose evaluation, 
performed based on point dose under treatment planning 
using CC13 chamber and point dose actually measured, 
showed that difference in pass rate was 1.2% in multiple 
targets, 1.5% in prostate, 1.3% in head & neck, and 0.4% in C 
TYPE. 
 
Conclusion: This study may provide useful basis for ensuring 
quality assurance for each patient by using the MLC log 
analysis system during special treatments in clinical 
applications. 
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Purpose or Objective: The aim of this study was to assess 
the accuracy of the dosimertic algorithm based on the 
resolution of Boltzmann equation: “Acuros XB” (AXB) 
implemented in Eclipse (Varian) TPS. The methodology 
recommended by the IAEA-TECDOC-1583 was followed to 
evaluate AXB. AXB was also tested for clinical extra cranial 
stereotactic treatment cases. Moreover AXB with the two 
absorbed dose reporting options, dose-to-medium (Dm) and 
dose-to-water (Dw), was compared against the Analytical 
Anisotropic Algorithm (AAA). 
 
Material and Methods: The IAEA-TECDOC-1583 presents eight 
different fields configurations in heterogeneous media. All 
plans were created on a CIRS thorax phantom model 002LFC 
including different tissue equivalent inserts (water, bone and 
lung). Measurements were performed with a PinPoint 
ionization chamber (type 31016, PTW) on Novalis TrueBeam 
STx accelerator for 6MV and 10MV photons with and without 
flattening filter (6FF, 6FFF, 10FF, 10FFF). Furthermore, 
target absorbed dose difference between AXB (Dm and Dw) 
and AAA were compared using same monitor units for 17 
patients with non-small-cell lung cancer (NSCLC) or bone 
metastases cancer who underwent SBRT. 
 
Results: AXB Dm calculations showed an excellent agreement 
with measurements for the eight configurations of the IAEA-
TECDOC-1583. All the results fulfilled the agreement 
criterion given in the IAEA-TECDOC-1583. The biggest 
difference between measured and calculated absorbed dose 
with AXB (Dm and Dw) in lung was less than 0.6% for all 
photon energies. Unlike, in the lung region, AAA showed 
deviations that didn’t met the agreement criterion. Maximum 
deviations were 4.4%, 3.35%, 2.27% and 1.6% for respectively 
6FF, 10FF, 6FFF and 10FFF photon energies. Although the Dm 
and Dw was almost the same in most tissues for all the 
energies, comparing them in bony structure didn’t give 
similar results. When choosing Dw in the bone region some 
results didn’t fulfilled the agreement criterion, unlike Dm 
where excellent agreement were found between calculated 
and measured absorbed dose. For the planning target volume 
(PTV) in the NSCLC patients, AXB Dm and Dw calculations 
showed similar results while compared to the AAA 
calculations, where the average differences were less than 
2% for minimum, mean and maximum absorbed doses. For 
bone metastases cancer patients, comparing the PTV doses 
between AXB Dm and AXB Dw didn’t show similar results. The 
averaged deviations between AXB Dm and AAA were 1.7%, 
0.1% and 2.2% whereas deviations between AXB Dw and AAA 
were 0.1%, 4.2% and 0.7%, respectively for minimum, 
maximum and mean absorbed doses. 
 
Conclusion: The results of the IAEA-TECDOC-1583 and of 
clinical cases showed that the AXB algorithm is more 
accurate than AAA in the lung region for 6FF, 10FF, 6FFF and 
10FFF photons. As for bone metastasis the use of AXB Dm was 
recommended. 
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